Drug Trial Radar · NCT05843643
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,014
Actual
Start
Jul 25, 2023
Primary completion
Mar 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 63 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions
- Systemic Lupus Erythematosus
Interventions
UpadacitinibDrug
Oral Tablets
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) ResponseTime frame: At Week 52
Locations
369 sites in 38 countries. Site status is shown where the registry gives one.
AZ Arthritis and Rheumatology /ID# 261848
Chandler, Arizona
AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767
Flagstaff, Arizona
Arizona Arthritis & Rheumatology Research, PLLC /ID# 252820
Gilbert, Arizona
Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 252824
Glendale, Arizona
Arizona Arthritis & Rheumatology Research, PLLC /ID# 261845
Mesa, Arizona
Arizona Arthritis & Rheumatology Research /ID# 273555
Peoria, Arizona
Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 252831
Phoenix, Arizona
Arizona Arthritis & Rheumatology Research, PLLC /ID# 252825
Phoenix, Arizona
HonorHealth Rheumatology /ID# 261953
Scottsdale, Arizona
Arizona Arthritis & Rheumatology Associates - Tucson /ID# 252828
Tucson, Arizona
Arthritis and Rheumatism Associates /ID# 253033
Jonesboro, Arkansas
Kaiser Permanente Lakeview Medical Offices /ID# 253906
Anaheim, California
David S. Hallegua MD, A Professional Corporation /ID# 253902
Beverly Hills, California
Wallace and Lee Center /ID# 275129
Beverly Hills, California
Wallace Rheumatic Studies Center, LLC /ID# 252806
Beverly Hills, California
Advanced Clinical Research Center, LLC dba TriWest Research Associates /ID# 272870
Chula Vista, California
Providence - St. Jude Medical Center /ID# 252822
Fullerton, California
Private Practice - Dr. Chandrakant V. Mehta /ID# 275100
Hemet, California
Newport Huntington Medical Group /ID# 252827
Huntington Beach, California
Moores Cancer Center at UC San Diego /ID# 253903
La Jolla, California
Arthritis & Osteo Medical Ctr /ID# 252812
La Palma, California
Wagdy Kades, M.D., Inc /ID# 272065
Los Angeles, California
Providence St. Johns Health Center /ID# 253905
Santa Monica, California
Millennium Clinical Trials /ID# 252817
Thousand Oaks, California
Cohen Medical Centers /ID# 268524
Thousand Oaks, California
Solace Research /ID# 275198
Tustin, California
Upland Rheumatology Center /ID# 268623
Upland, California
University of Colorado Hospital /ID# 253184
Aurora, Colorado
Denver Arthritis Clinic /ID# 253189
Denver, Colorado
Yale University School of Medicine /ID# 254567
New Haven, Connecticut
Arthritis and Rheumatic Disease Specialties /ID# 253624
Aventura, Florida
HARAC Research Corp. /ID# 254922
Avon Park, Florida
Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 253623
Boca Raton, Florida
Mdr Core Network, Inc /Id# 276704
Boynton Beach, Florida
Bay Area Arthritis and Osteo /ID# 253597
Brandon, Florida
GNP Consultants, dba, GNP Research /ID# 272868
Cooper City, Florida
Duplicate_Believe Clinical Trials /ID# 255427
Coral Springs, Florida
International Medical Research /ID# 253617
Daytona Beach, Florida
Omega Research Debary, LLC /ID# 254939
DeBary, Florida
University of Florida /ID# 261984
Gainesville, Florida
Showing 40 of 369 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.